Ionis Q2 adjusted operating loss narrows

Overview

• RNA medicines developer's Q2 adjusted operating loss narrows

• Q2 commercial revenue rose 15% yr/yr, driven by DAWNZERA product sales

• Higher Q2 operating expenses due to commercialization and launch investments

Outlook

• Company expects full-year 2026 TRYNGOLZA product sales of $100-110 mln

• Ionis expects full-year 2026 DAWNZERA product sales of $110-120 mln

• Company says it remains on track to achieve 2026 financial guidance

Result Drivers

• NEW PRODUCT LAUNCHES - Co said early launch momentum for TRYNGOLZA in severe hypertriglyceridemia and strong DAWNZERA sales drove commercial revenue growth

• COMMERCIALIZATION INVESTMENTS - Higher operating expenses mainly due to investments in commercialization efforts for TRYNGOLZA, DAWNZERA, and launch preparations for zilganersen

• R&D COLLABORATIONS - Growth in research and development revenue attributed to multiple payments for advancing programs under R&D collaborations, excluding prior-year one-time payment

Company press release: ID:nBw6cVFzRa

Key Details

Reuters Recommended Reads

• July 28 - Incyte beats Q2 revenue estimates on strong product demand

• July 29 - Biogen Q2 revenue beats expectations on strong product demand

• July 27 - Argenx to buy Forte Biosciences for about $2.2 billion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)